ADVA
30.4.2020 09:02:05 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that dacoso has deployed its ConnectGuard™ Cloud encryption solution for robust software-based network protection. By leveraging the industry-first cloud-native technology, the IT service provider is ensuring end-to-end security for its virtual private network (VPN). The cost-effective and low-latency solution is now safeguarding connectivity between dacoso’s data centers in Germany, Austria and Switzerland, as well as its virtual cloud services. The deployment improves dacoso’s bandwidth efficiency while complying with all relevant industry standards. Also, by moving to a cloud-native security solution, dacoso’s mission-critical network benefits from enhanced flexibility and cost-efficiency.
“By deploying ADVA’s ConnectGuard™ Cloud technology, we’re harnessing virtualized encryption that’s flexible, scalable and doesn’t come with a heavy bandwidth penalty. The solution ensures rigorous data protection for both our branches and our cloud locations. And, because it works without large additional data ballast, it also improves network utilization and reduces cost-per-encrypted-bit,” said Karsten Geise, head of business and product development, dacoso. “Now our cloud network meets all regulatory requirements, such as GDPR, while being simpler and more efficient. Removing the need for hardware appliances also frees up valuable rack space and means we can easily shop around for new innovation in the future rather than being constrained by single-vendor lock-in.”
dacoso provides managed services for businesses that rely on the highest levels of security, including virtual environments. As hardware-based encryption isn’t possible in cloud provider data centers, the software-based protection that ConnectGuard™ Cloud offers is vital. Based on ADVA’s industry-leading Ensemble Connector virtualization platform, the solution delivers a host of benefits. These include end-to-end encryption at Layer 2, 3 and 4, along with improved latency and throughput performance compared to IPSec. With its zero-touch provisioning and automated key management, ADVA’s unique cloud-native technology also significantly simplifies operations for dacoso’s team. Complexity is further reduced by automated key distribution and management, centrally orchestrated by the ADVA Ensemble Controller management solution.
“dacoso now has all the advantages of highly efficient and extremely rigorous encryption, delivered entirely through software. That means ultra-low latency protection at Layers 2, 3 and 4, as well as unrivaled advantages in terms of scale and ease of use,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “ConnectGuard™ Cloud really is the ultimate solution for site-to-site and site-to-cloud encrypted VPNs. It’s also the perfect fit for dacoso’s needs. With transport-layer independent security, they can rely on comprehensive protection that won’t affect the performance of the services it provides. What’s more, as part of our Ensemble portfolio of open NFV solutions, ConnectGuard™ Cloud unshackles dacoso from vendor lock-in and offers freedom to mix and match new technologies in the future.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About dacoso
dacoso offers solutions for Connectivity, Cyber Security and Virtual Networking. The IT service provider thereby addresses companies that need their data to be highly available and secure yet without sacrificing agility. dacoso services comprise, among other, optical data links encrypted to satisfy BSI, a certified Security Operation Center, Managed Security Services and virtualization solutions to increase the dynamic performance of networks. dacoso GmbH is an owner-managed company headquartered in Langen, Frankfurt a.M., with a further 11 locations in Germany, Austria and Switzerland. www.dacoso.com
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005022/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom